Innovative Therapeutics Statera BioPharma specializes in restoring immune health through complex, pleiotropic drugs targeting disease resolution and homeostasis, presenting a unique opportunity to collaborate with health providers seeking advanced immune-modulating therapies.

Strategic Asset Licensing The recent licensing agreement with Tivic Health for the TLR5 agonist program, including Entolimod, provides a potential avenue for sales in acute radiation syndrome treatments and other immune-related indications, especially within government and emergency response sectors.

Partnership Expansion Recent collaborations with Holobeam Technologies and strategic mergers, such as with Worksite Labs, indicate openness to expanding distribution channels and diagnostic solutions, offering potential sales opportunities across biotech and diagnostic markets.

Financial & Market Potential Despite current financial constraints with a revenue range of one to ten million dollars and recent funding of 1.1 million, the company's strategic partnerships and licensing deals suggest opportunities for growth and eventual market expansion in biotech and healthcare sectors.

Size and Flexibility With a small team of 2-10 employees, Statera offers an agile partner profile for personalized engagement, enabling tailored sales approaches and collaborative development opportunities in niche biopharmaceutical and immune health markets.